EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy

Eleftheria Kampouri iD, Sarah S Ibrahimi, Hu Xie, Elizabeth R Wong, Jessica B Hecht, Mandeep K Sekhon, Alythia Vo, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, David G Maloney, Ailyn Perez und 4 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Eleftheria Kampouri und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Swiss National Science Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The epidemiology of cytomegalovirus (CMV) after chimeric antigen receptor–modified T-cell immunotherapy (CARTx) is poorly understood owing to a lack of routine surveillance.

Methods

We prospectively enrolled 72 adult CMV-seropositive CD19-, CD20-, or BCMA-targeted CARTx recipients and tested plasma samples for CMV before and weekly up to 12 weeks after CARTx. We assessed CMV-specific cell-mediated immunity (CMV-CMI) before and 2 and 4 weeks after CARTx, using an interferon γ release assay to quantify T-cell responses to IE-1 and pp65. We tested pre-CARTx samples to calculate a risk score for cytopenias and infection (CAR-HEMATOTOX). We used Cox regression to evaluate CMV risk factors and evaluated the predictive performance of CMV-CMI for CMV reactivation in receiver operator characteristic curves.

Results

CMV was detected in 1 patient (1.4%) before and in 18 (25%) after CARTx, for a cumulative incidence of 27% (95% confidence interval, 16.8–38.2). The median CMV viral load (interquartile range) was 127 (interquartile range, 61–276) IU/mL, with no end-organ disease observed; 5 patients received preemptive therapy based on clinical results. CMV-CMI values reached a nadir 2 weeks after infusion and recovered to baseline levels by week 4. In adjusted models, BCMA-CARTx (vs CD19/CD20) and corticosteroid use for >3 days were significantly associated with CMV reactivation, and possible associations were detected for lower week 2 CMV-CMI and more prior antitumor regimens. The cumulative incidence of CMV reactivation almost doubled when stratified by BCMA-CARTx target and use of corticosteroids for >3 days (46% and 49%, respectively).

Conclusions

CMV testing could be considered between 2 and 6 weeks in high-risk CARTx recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsReceptors, Chimeric AntigenAdultHumansCytomegalovirusB-Cell Maturation AntigenImmunity, CellularCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CARCMVchimeric antigen receptorcytomegalovirusimmunotherapy

Substanzen

Receptors, Chimeric AntigenB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

ORCID-Profile: Eleftheria Kampouri

Förderung

  • NCI NIH HHS
  • Swiss National Science Foundation
  • NIH HHS
  • SICPA Foundation
  • National Institutes of Health

Zitieren

APA

Kampouri, E., Ibrahimi, S. S., Xie, H., Wong, E. R., Hecht, J. B., Sekhon, M. K., Vo, A., Stevens-Ayers, T. L., Green, D. J., Gauthier, J., Maloney, D. G., Perez, A., Jerome, K. R., Leisenring, W. M., Boeckh, M. J., & Hill, J. A. (2024). Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad708

Vancouver

Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, et al. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad708

BibTeX
@article{Kampouri2024,
  author = {Kampouri, Eleftheria and Ibrahimi, Sarah S and Xie, Hu and Wong, Elizabeth R and Hecht, Jessica B and Sekhon, Mandeep K and Vo, Alythia and Stevens-Ayers, Terry L and Green, Damian J and Gauthier, Jordan and Maloney, David G and Perez, Ailyn and Jerome, Keith R and Leisenring, Wendy M and Boeckh, Michael J and Hill, Joshua A},
  title = {Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad708}
}
Kostenlos starten →